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Summary
Impaired calcium homeostasis and altered expression of Ca2+-binding proteins are associated with cardiomyopathies,
myocardial hypertrophy, infarction or ischemia. S100A1 protein with its modulatory effect on different target proteins
has been proposed as one of potential candidates which could participate in these pathological processes. The exact
localization of S100A1 in human heart cells on the ultrastructural level accompanied with biochemical determination of
its target proteins may help clarify the role of S100A1 in heart muscle. In the present study the distribution of the
S100A1 protein using postembedding (Lowicryl K4M) immunocytochemical method in human heart muscle has been
determined quantitatively, relating number of antigen sites to the unit area of a respective structural component.
S100A1 antigen sites have been detected in elements of sarcoplasmic reticulum (SR), in myofibrils at all levels of
sarcomere and in mitochondria, the density of immunolabeling at Z-lines being about 3 times and at SR more than
5 times higher than immunolabeling of remaining structural components. The presence of the S100A1 in SR and
myofibrils may be related to the known target proteins for S100A1 at these sites.
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Introduction
Calcium ions as second messengers play an
important role in the regulation of large number of
cellular processes such as muscle contraction, secretion,
cell division, cell cycle progression, energy production,
proliferation, gene transcription and differentiation
(Berridge 1997). The key molecules to transduce Ca2+
signaling are Ca2+-binding proteins mainly belonging to
the large EF-hand protein superfamily (Heizmann and
Hunziker 1991, Kawasaki et al. 1998).
Since the first isolation of S100 proteins from
bovine brain (Moore 1965) they have become the largest
subfamily of EF-hand Ca2+-binding proteins (Zimmer et
al. 1995, Schäfer and Heizmann 1996, Heizmann and
Cox 1998, Donato 1999). S100 proteins are acidic
proteins of low molecular weight (10-12 kDa) and are
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characterized by two distinct EF-hand domains with
different affinities for Ca2+. To date, 19 different proteins
which display various degree of amino acid sequence
homology, have been assigned to the S100 protein family
(Donato 1999). A new S100 nomenclature is based on the
clustered organization of at least 13 S100 genes on
human chromosome 1q21 (Engelkamp et al. 1993,
Heizmann and Schäfer 2001) and mouse chromosome 3,
respectively (Ridinger et al. 1998).
S100 proteins show tissue- and cell-specific
expression, a characteristic they share with most other
EF-hand Ca2+-binding proteins but not with the
multifunctional and ubiquitously expressed calmodulin
(Crivici and Ikura 1995). S100 proteins mainly exert their
modulatory effect through Ca2+-regulated interactions
with intracellular specific target proteins.
Although both S100A1 and S100B were
originally assumed to be neuronal specific proteins, it is
now clear that S100A1 is specifically expressed in slow-
twitch skeletal and heart muscles (for review see
Heizmann and Cox 1998, Donato 1999).
Ultrastructural localization studies of the
S100A1 in skeletal (Haimoto and Kato 1987, Maco et al.
1997, 1999, 2000a) and heart muscle cells (Haimoto and
Kato 1988) have been done mostly in rodents and have
localized S100A1 in myofibrils associated with actin and
myosin filaments and with Z-lines, in the sarcoplasmic
reticulum, in mitochondria, along the sarcolemma, and in
fascia adherens of the intercalated discs.
Expression and localization of S100 proteins in
human tissues may differ from that in rodent tissues
(Engelkamp et al. 1992). However, no corresponding
ultrastructural studies have been performed in human
heart. Changes in expression of S100A1 in human
cardiomyopathy (Remppis et al. 1996) and a right
ventricular upregulation of S100A1 in chronic pulmonary
hypertension (Ehlermann et al. 2000) indicate that more
attention should be paid to the role of S100A1 and
probably also of other calcium binding proteins in cardiac
diseases. In addition, the increased level of S100A1 in the
serum after myocardial infarction with the possibility to
differentiate between infarction and angina pectoris (Usui
et al. 1990) suggests a potential diagnostic value of this
protein.
The importance of a distinct subcellular location
of S100A1 for the cell function under normal and
pathologic conditions would be more evident if
quantitative data on the distribution of antigens in relation
to structure would be available. In the present
ultrastructural study the distribution of S100A1 protein
using immunocytochemical method in human heart was
determined quantitatively, relating number of antigen
sites to the unit area of a respective structural component.
Methods
Tissue preparation
Pieces of human heart muscle from the right
atrium were obtained during surgery of a 34-years old
man with a mitral valve disease in accordance with
Helsinki Declaration of 1975.
Fixation and preparation of sections
The heart biopsy samples were immediately
fixed for 1 h at 4 °C in 0.5 % glutaraldehyde (Fluka,
Buchs, Switzerland) and 3 % paraformaldehyde (Merck,
New Jersey, USA) in 10 mmol/l phosphate buffer
solution (PBS) containing (mmol/l): Na2HPO4 (10),
NaH2PO4 (10), NaCl (85.5), NaN3 (20), pH 7.4. Fixed
specimens were then dehydrated in ethanol, embedded in
Lowicryl K4M (Polysciences, Eppelheim, Germany) and
polymerized under UV light at 40 °C. Grey/silver
sections were mounted on parlodion-coated copper grids
(200 mesh). Sections were washed with 2 % BSA
(Boehringer, Mannheim, Germany) in 10 mmol/l PBS
before incubation with antibodies (see below) and stained
with 6% aqueous uranyl acetate (Fluka, Buchs,
Switzerland) and lead citrate.
EM immunocytochemistry
Ultrathin sections were labeled with purified
polyclonal antiserum obtained by immunization of goats
with recombinant human S100A1 protein produced in
E. coli cultures (Ilg et al. 1996). The serum was diluted
1:300 with 2 % BSA in PBS and applied for one hour.
The sections were then washed in PBS, and exposed for
1 h to the rabbit anti-goat secondary antibody coupled
with 15-nm gold (Aurion, Wageningen, Netherland) and
diluted 1:20 with 2 % BSA in PBS. Stainings with
primary antibodies preabsorbed with human recombinant
S100A1 protein were used as control.
Prior to application all antibodies were sonicated
in water (Sonorex, TK 52H, Berlin, Germany) for 2-3 s.
The sections were examined in a Philips EM 400
(Holland) electron microscope at 80 kV, photographed
(negatives Kodak SO-163, USA), and printed with total
magnification of 17 500× for immunogold counting.
Particle counting
The densities of gold particles on different levels
of sarcomere (Z-line, I-band, and A-band), sarcoplasmic
reticulum, mitochondria and sarcoplasm of human heart
muscle cells were obtained from longitudinal sections.
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Three different blocks of tissue were used. From each
block 3 different grids with sections were prepared.
Sixteen micrographs were taken from each grid and
printed at total magnification of 17 500×.
Areas (µm2) of immunolabeled structural
components (Ac) of myofibrils were estimated by the
point counting method (Weibel and Bolender 1973) from
each micrograph:  Ac=Σpx × (d/mag)2   where p is
number of points of two-dimensional test lattice for
particular structural components of myofibrils; d is
distance of two neighboring points of the test grid (µm),
and mag is total magnification of a micrograph. The
density of immunolabeling was expressed as the number
of gold particles per unit area of the respective structural
component. Background labeling was estimated in a
similar manner.
Table 1. Immunogold labeling of individual blocks at particular structural components.
Gold particles/µm2
Block 1 Block 2 Block 3
Z-line 0.2592 ± 0.0188 0.2883 ± 0.0659 0.6931 ± 0.0802
I-band 0.0318 ± 0.0246 0.1249 ± 0.0364 0.3336 ± 0.0243
A-band 0.0501 ± 0.0087 0.0920 ± 0.0141 0.1454 ± 0.0117
mitochondria 0.0618 ± 0.0134 0.1249 ± 0.0289 0.2946 ± 0.0110
sarcoplasmic reticulum 0.4531 ± 0.2003 0.8973 ± 0.3145 1.1794 ± 0.0418
remaining sarcoplasm 0.1079 ± 0.0577 0.0584 ± 0.0158 0.1642 ± 0.0211
Label over empty plastic of 0.1839 particles/µm2 has been subtracted. Each block is represented by
three sets of data pooled from 16 micrographs obtained from individual grids with sections. Data are
expressed as number of gold particles per µm2; mean values ±  S.E.M.
Fig. 1. Ultrastructural localization of S100A1 protein in human heart muscle at different levels of sarcomere. (A)
Presence of gold particles on Z-line (arrows); (B) on I-band (arrowhead) and M-line (arrow); (C) on M-line (arrow)
and on H-band (asterisk); (D) on A-band (arrowheads), I-band (thin arrow) and Z-line (thick arrow). Bars:
A = 0.3 µm; B-D = 0.5 µm.
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Fig. 2. The presence of S100A1 protein in elements of the
sarcoplasmic reticulum (arrows). Bars: A-C = 0.5 µm;
D = 0.3 µm.
Results
Immunogold electron microscopy of S100A1
distribution in longitudinal sections of normal human
heart showed that antigen sites for S100A1 protein were
localized mainly in myofibrils at all levels of sarcomere
(Fig. 1) and in elements of sarcoplasmic reticulum (SR)
(Fig. 2).
The staining with immunogold on other
structural components as intercalated discs, sarcolemma
and nuclei was sparse. In an effort to suppress
nonspecific immunolabeling as much as possible some
specific labeling could have been suppressed as well.
However, no immunolabeling occurred in controls
(Fig. 3).
Immunogold particles were not uniformly
distributed but occurred preferentially at particular
locations. As summarized in Table 1, the most preferred
locations were Z-lines (Figs 1A and 1D) and elements of
SR (Fig. 2).
A lower density of S100A1 protein was
observed on thin and thick myofilaments (Figs 1B and
1D). Within the A-bands a slightly higher density of
immunogold particles was detected on M-lines (Figs 1B
and 1C).
To compensate for differences in
immunolabeling between individual blocks (Table 1)
resulting probably from different time intervals between
sectioning and immunolabeling or from differences in
blocking conditions, the immunogold densities at
particular structural components were normalized to
corresponding immunogold densities of mitochondria.
The normalized densities are shown in Figure 4.
It is evident that density of immunolabeling on Z-line is
about 3 times and in case of SR more than 5 times higher
than immunolabeling of remaining structural
components. These differences are significant (p<0.05).
Discussion
A precise control of Ca2+ homeostasis in cardiac
muscle cells is a prerequisite for normal function and its
derangement results in various pathological states.
Ultrastructural localization studies of S100A1 may
contribute to elucidation of subcellular mechanisms of
Ca2+-signaling and give us insight into processes resulting
in pathological heart.
 To our knowledge, the ultrastructural
localization and quantitative evaluation of S100A1
distribution in normal human heart has been performed
for the first time in the present study. Although S100A1
may be found in different compartments of the heart cell,
two areas of the highest occurrence, the Z-line and the
elements of the sarcoplasmic reticulum, could be
identified. Total amount of S100A1 protein expressed by
human heart is 1.84±0.5 µg/mg protein which is about
twofold higher than that of human skeletal muscle (Kato
and Kimura 1985).
A relatively sparse immunogold staining in the
present study may result from several reasons: a) strong
blocking conditions during specimen preparation; b) the
lower S100A1 expression in atrial than in ventricular
myocardium (as described during mouse heart
development, Kiewitz et al. 2000); c) the lower S100A1
expression in the right heart in comparison with the left
ventricle (as described for porcine myocardium, Remppis
et al. 1996). It is not clear if the underlying mitral valve
disease could have an effect on the S100A1 expression in
the right atrium. There were no clinical signs of right
atrium dysfunction.
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Fig. 4. Normalization of immuno-gold densities at
particular structural components (IDstr) to corresponding
immunogold densities of mitochondria (IDm). Data are
means ± S.E.M.; *p<0.05 with respect to the
I-band, A-band and remaining sarcoplasm.
The presence of antigen sites for S100A1 along
the sarcomere (Figures 1A-D) suggests an association of
S100A1 with contractile filaments and/or with some
other components associated with myofibrils. While an
interaction of S100A1 with skeletal muscle myosin heavy
chain has been detected by gel overlay technique
(Zimmer 1991), an interaction with cardiac myosin heavy
chain has not been observed (Donato et al. 1989). These
differences could be due to the different myosin isoforms
in cardiac and skeletal muscle fibers. Recently
Mandinova et al. (1998) have shown a direct interaction
of S100A1 protein with rabbit skeletal F-actin in Ca2+-
dependent manner in vitro and with actin stress fibers of
human smooth muscle cells.
Location of antigen sites at M-lines (Figs 1B and
1C) may be interesting since M-lines are a site of titin
kinase (Labeit et al. 1997) which is equivalent to twitchin
kinase in invertebrates. Twitchin kinase is regulated by
S100A1 and it is assumed that cardiac titin may be
regulated in a similar way (Heierhorst et al. 1996, 1997).
The high concentration of immunogold particles seen at
the Z-line (Figs 1A and 1D) may result from a
combination of interaction of S100A1 binding to F-actin
and CapZ, the actin capping protein (Ivanenkov et al.
1996). S100A1 protein interacts with CapZ protein at the
same binding site as phosphatidylinositol 4-
monophosphate (PIP), a regulator of CapZ activity. It is
assumed that S100A1 protein modulates the inhibitory
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effect of PIP on activity of CapZ protein and can
participate in the regulation of length, orientation and/or
anchoring of actin filaments to the Z-line (Caldwell et al.
1989, Xu et al. 1999).
The location of S100A1 antigens at the
sarcoplasmic reticulum observed in our study (Fig. 2)
corresponds to similar findings from mouse (Haimoto
and Kato 1988) and porcine heart (Donato et al. 1989) or
rat skeletal muscle (Haimoto and Kato 1987, 1999, Maco
et al. 1997, 2000a). It may be related to S100A1
stimulation of Ca2+-induced Ca2+ release from isolated SR
vesicles (Fanò et al. 1989b, Marsili et al. 1992), to
increased caffeine-induced Ca2+ release by S100A1 in
permeabilized fast and slow twitch skeletal muscle fibers
(Weber et al. 1997) and to interaction of S100A1 with the
ryanodine receptor (Treves et al. 1997). The localization
of S100A1 at the level of SR could also be related to its
stimulatory effect on the basal activity of adenylate
cyclase (Fanò et al. 1989a) associated with the
sarcolemma, T-tubules and junctional SR where this
enzymatic complex has been identified histochemically
(Slezak and Geller 1984; for review see Schulze and
Buchwalow 1998).
The growing list of S100A1 target proteins also
includes some enzymes of energy metabolism such as
glycogen phosphorylase a and phosphoglucomutase (for
review see Zimmer et al. 1995, Landar et al. 1996) in
slow-twitch skeletal muscle. Although many
glycogenolytic and glycolytic enzymes are preferentially
bound to F-actin (Arnold and Pette 1968) both above-
mentioned enzymes are associated with the membranes of
SR (Entam et al. 1976, Lee et al. 1992). Recently, other
glycolytic enzymes were also found to be localized on
cytoplasmic surface of rabbit skeletal and heart SR
vesicles and it was suggested that the ATP generated by
SR-associated glycolytic enzymes may be coupled to SR
active calcium transport (Xu and Becker 1998).
Another hypothesis how to explain the presence
of S100A1 antigen sites at the level of SR is provided by
gel-overlay experiments performed by Zimmer (1991)
who found an interaction of S100A1 with different SR
proteins. Two of these proteins with the molecular
weights of 30 kDa and 100 kDa could be tentatively
identified as phospholamban and Ca2+-ATPase
(SERCA2), respectively. Thus S100A1 may not only be
involved in the Ca2+ release from SR but could also play
a role in the calcium uptake into SR. In such a case
S100A1 would be an interesting candidate to explain the
impaired Ca2+-homeostasis in dilated cardiomyopathy
(Minamisawa et al. 1999).
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